Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) [EARLY_Phase 1]

View source ↗

Summary

This is an early Phase 1 dose-escalation trial evaluating a combined CD19/CD22/BCMA CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19/CD22/BCMA CAR-T therapy (CAR-T therapy targeting CD19, CD22, and BCMA)

Snippet

Sponsor: Shanghai Cell Therapy Group Co.,Ltd | Conditions: Non-Hodgkin Lymphoma, B-cell | EARLY_Phase 1 | Status: RECRUITING